NEW THERAPEUTIC PERSPECTIVES IN IRRITABLE BOWEL SYNDROME: TARGETING LOW-GRADE INFLAMMATION, IMMUNO-NEUROENDOCRINE AXIS, MOTILITY, SDECRETION AND BEYOND

Giovanni Tomasello, Valentina Guarnotta, Francesco Cappello, Dario Raimondo, Emanuele Sinagra, Georgios Amvrosiadis, Gaetano Cristian Morreale, Francesca Rossi, Ghazaleh Mohammadian, Giorgio Fusco, Dario Raimondo, Giovanni Tomasello, Francesco Cappello, Francesco Cappello

Risultato della ricerca: Articlepeer review

23 Citazioni (Scopus)

Abstract

Irritable bowel syndrome (IBS) is a chronic, recurring,and remitting functional disorder of the gastrointestinaltract characterized by abdominal pain, distention, andchanges in bowel habits. Although there are severaldrugs for IBS, effective and approved treatments forone or more of the symptoms for various IBS subtypesare needed. Improved understanding of pathophysiologicalmechanisms such as the role of impaired bileacid metabolism, neurohormonal regulation, immune, dysfunction, the epithelial barrier and the secretoryproperties of the gut has led to advancements in thetreatment of IBS. With regards to therapies for restoringintestinal permeability, multiple studies with prebioticsand probiotics are ongoing, even if to date their efficacyhas been limited. In parallel, much progress has beenmade in targeting low-grade inflammation, especiallythrough the introduction of drugs such as mesalazineand rifaximin, even if a better knowledge of themechanisms underlying the low-grade inflammation inIBS may allow the design of clinical trials that test theefficacy and safety of such drugs. This literature reviewaims to summarize the findings related to new andinvestigational therapeutic agents for IBS, most recentlydeveloped in preclinical as well as Phase 1 and Phase 2clinical studies.
Lingua originaleEnglish
pagine (da-a)6593-6627
Numero di pagine35
RivistaWorld Journal of Gastroenterology
Volume23
Stato di pubblicazionePublished - 2017

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2715???

Fingerprint

Entra nei temi di ricerca di 'NEW THERAPEUTIC PERSPECTIVES IN IRRITABLE BOWEL SYNDROME: TARGETING LOW-GRADE INFLAMMATION, IMMUNO-NEUROENDOCRINE AXIS, MOTILITY, SDECRETION AND BEYOND'. Insieme formano una fingerprint unica.

Cita questo